Afamelanotide
- TRADE NAMES: Melanotan (Clinuvel); Scenesse (Clinuvel)
- INDICATIONS: Erythropoetic protoporphyria, polymorphous light eruption, photodamage
- CLASS: Melanocortin receptor agonist, Melanocyte stimulating hormone A agonist, Photoprotective
- HALF-LIFE: ~15 hr when administered subcutaneously in a controlled release implant.
FDA APPROVAL DATE: 10/08/2019 (as an implant)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
There are no data in pregnant women to evaluate for any drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric